5F-PB-22 is an ester-type synthetic cannabinoid that acts as a full agonist at cannabinoid receptors CB1 and CB2 (EC50 = 2.8 nM and 11 nM, respectively)1. Activation of the receptors results in Gi/o-dependent functional inhibition of adenylate cyclase, leading to reduced intracellular cAMP levels. In vitro, 5F-PB-22 showed toxicity in cardiac and neuronal cell lines2. Studies on mice models show it more effectively triggers a number of biological processes, including activation of G-protein-gated inwardly rectifying K+ channels, when compared to Δ9-THC3. In vivo responses on experimental mice models are in line with other synthetic cannabinoid receptor agonists and show suppression of locomotor activities as well as induction of hypothermia and bradycardia3.